Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
Authors' conclusion
We conclude that tirzepatide is an effective treatment for the most common genetic subtype of obesity, MC4R deficiency.
Study context
- Population
- Men and women with obesity in the SURMOUNT-1 trial of tirzepatide (dual GLP-1 and GIP receptor agonist) with genetic data availabledata available
- Participants
- 2,291 men
- Comparison
- MC4R mutation carriers vs noncarriers treated with tirzepatide
- MC4R mutation carriersn = 32
Methodological detailsgenetic subgroup analysis
- Genetic subgroup analysis
Primary result
As reported in the abstract
Weight reduction in the tirzepatide arm · 72 weeks
Further findings
BMI at baseline · higher in carriers
P = 0.036
| Outcome | MC4R mutation carriers | Noncarriers |
|---|---|---|
| Prevalence of pathogenic MC4R mutations | 1.4% | — not stated in the abstract |
— not stated in the abstract
Original publication
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency. Nat Med. Published 26 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →